Assessing 3SBio (SEHK:1530) Valuation After Strong 2025 Earnings And Affirmed Dividend

Why 3SBio’s latest earnings and dividend decision matter

3SBio (SEHK:1530) has drawn fresh attention after reporting full year 2025 results alongside a reaffirmed final dividend. This combination puts both profitability and cash returns to shareholders in focus.

The company reported sales of CNY 17,695.75 million and net income of CNY 8,482.16 million for 2025, with basic earnings per share from continuing operations at CNY 3.51 and diluted earnings per share at CNY 3.43.

See our latest analysis for 3SBio.

Alongside the earnings and dividend news, 3SBio’s share price has been volatile, with a 1 month share price return of 8.10% but a 3 month share price return decline of 16.99%. The 1 year total shareholder return is 86.65%, indicating strong longer term momentum despite recent weakness.

If you are weighing 3SBio’s latest move against other healthcare names using AI, this could be a good moment to scan the market with 122 healthcare AI stocks

With strong recent earnings, an affirmed dividend, and the shares trading at what some might see as a sizable discount to analyst targets, investors now have to ask: is this a buying opportunity, or is future growth already reflected in the current share price?

Preferred P/E of 5.9x: Is it justified?

At HK$22.96, 3SBio trades on a P/E of 5.9x, which screens as inexpensive compared to both its own fair P/E estimate and the wider biotech peer group.

The P/E ratio compares the current share price to earnings per share and is a quick way to see how much investors are paying for current profits. For a profitable biopharmaceutical business with CNY 8,482.16 million in net income and a history of strong earnings growth, a low P/E can signal that the market is hesitant to pay up for those earnings.

What stands out is how far this multiple sits below other reference points. 3SBio’s P/E of 5.9x is described as good value versus an estimated fair P/E of 10.4x, a level the market could potentially move toward if sentiment changed. It is also well below the peer average P/E of 72.6x and the Asian biotechs industry average of 38.7x, which is a large gap for investors to weigh against the forecasts for declining earnings and revenue over the next three years.

Explore the SWS fair ratio for 3SBio

Result: Price-to-earnings of 5.9x (UNDERVALUED)

However, revenue and net income growth rates of 16.00% and 44.01% declines, together with recent share price volatility, could quickly challenge any simple undervaluation story.

Find out about the key risks to this 3SBio narrative.

Another view using our DCF model

While the 5.9x P/E points to inexpensive earnings, the SWS DCF model goes further, suggesting 3SBio at HK$22.96 trades below an estimated future cash flow value of HK$54.92. That is a sizeable gap. Is the market overly cautious, or are the cash flow assumptions too generous?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out 3SBio for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 231 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given this mix of risk and reward signals, it makes sense to look at the full picture yourself and decide how comfortable you are with the trade off. You can start with 3 key rewards and 1 important warning sign

Looking for more investment ideas?

Once you have formed a view on 3SBio, it makes sense to widen your watchlist so you are not relying on a single opportunity.

• Spot potential bargains early by scanning a curated set of screener containing 574 high quality undiscovered gems before they show up on everyone else's radar.
• Strengthen your core holdings by focusing on businesses highlighted in the solid balance sheet and fundamentals stocks screener (388 results) that pair financial resilience with dependable fundamentals.
• Target reliable portfolio income by reviewing the 480 dividend fortresses and zeroing in on companies offering yields from sturdy cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com